Prescriber and Infusion Center Locator icon

VYEPTI-Ready Provider and Infusion Center Locator

Find a healthcare provider or VYEPTI-ready infusion center in your area.

Meet Electra, a real VYEPTI patient with chronic migraine

Meet Electra

A real VYEPTI patient living with chronic migraine.

Resource Library icon

Resource Library

Explore VYEPTI resources that you can view, download, and share.

Patient Communications Resources icon

Patient Communication Resources

Discover VYEPTI resources, such as logos and reminder cards to use when communicating with patients.

Introducing VYEPTI Video thumbnail

Introducing VYEPTI Video

Learn about the clinical benefits and safety profile of VYEPTI from a physician.

VYEPTI: From Data to Patient Experience Video thumbnail

VYEPTI: From Data to Patient Experience Video

Watch Dr Dawn C Buse, PhD, and Dr Andrew C Charles, MD, as they speak with Electra, a real migraine patient treated with VYEPTI. Learn about efficacy and safety data for VYEPTI and patient considerations when selecting treatment.

VYEPTI Savings icon

Access Resources

Discover VYEPTI resources, such as VYEPTI CONNECT and VYEPTI Copay Program.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.